Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fludeoxyglucose F-18

FDA-approved product (injectable, injection), marketed as Fludeoxyglucose F18.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Fludeoxyglucose F-18
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Fludeoxyglucose F-18. Its therapeutic class is shown instead.

WHO therapeutic group
Other diagnostic radiopharmaceuticals for tumour detection
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Fludeoxyglucose F-18, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA18.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli6.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis13.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fludeoxyglucose F-18 in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fludeoxyglucose F-18 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)

    NCT00201942 · start 2005-02

    Registered record
    Registry ID
    NCT00201942
    Conditions
    Breast Cancer
    Interventions
    PET scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-02
    Completion
    2007-05
    Enrolment
    336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionPET scan
    PhasePhase 3
    Registry statusCompleted

  • 2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer

    NCT01821105 · start 2004-03

    Registered record
    Registry ID
    NCT01821105
    Conditions
    Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV A Bladder Cancer; Stage IV A Rectal Cancer; Stage IV B Colon Cancer; Stage IV B Rectal Cancer
    Interventions
    PET Scan; CT Scan; fludeoxyglucose F 18; computer-aided detection/diagnosis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-03
    Completion
    2009-11
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV A Bladder Cancer; Stage IV A Rectal Cancer +2 more
    InterventionPET Scan; CT Scan; fludeoxyglucose F 18; computer-aided detection/diagnosis
    PhasePhase 2
    Registry statusCompleted

  • Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

    NCT00043979 · start 2002-09-19

    Registered record
    Registry ID
    NCT00043979
    Conditions
    Sarcoma
    Interventions
    F-18 Fluorodeoxyglucose; therapeutic allogeneic lymphocytes; cyclophosphamide; cyclosporine; doxorubicin hydrochloride; etoposide; fludarabine phosphate; melphalan; prednisone; sirolimus; tacrolimus; vincristine sulfate; peripheral blood stem cell transplantation; Filgrastim; Peripheral Blood Stem Cell donation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-09-19
    Completion
    2011-12-14
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    InterventionF-18 Fluorodeoxyglucose; therapeutic allogeneic lymphocytes; cyclophosphamide; cyclosporine +11 more
    PhasePhase 2
    Registry statusCompleted

  • PET Scan in Treating Patients With Metastatic Prostate Cancer

    NCT00002981 · start 1997-01

    Registered record
    Registry ID
    NCT00002981
    Conditions
    Prostate Cancer
    Interventions
    positron emission tomography; fludeoxyglucose F 18; methionine C 11
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1997-01
    Completion
    2023-06-12
    Enrolment
    173

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionpositron emission tomography; fludeoxyglucose F 18; methionine C 11
    PhaseNot applicable
    Registry statusCompleted

  • Metabolic Abnormalities in Children With Epilepsy

    NCT00001325 · start 1992-04

    Registered record
    Registry ID
    NCT00001325
    Conditions
    Generalized Epilepsy; Infantile Spasms; Metabolic Disease; Partial Epilepsy; Seizures
    Interventions
    18 FDG
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1992-04
    Completion
    2004-06
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Epilepsy; Infantile Spasms; Metabolic Disease; Partial Epilepsy +1 more
    Intervention18 FDG
    PhaseNot recorded
    Registry statusCompleted